Showing 2231-2240 of 2351 results for "".
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
- National Psoriasis Foundation Launches Patient-centered Research Platformhttps://practicaldermatology.com/news/national-psoriasis-foundation-launches-patient-centered-research-platform/2458902/Patients with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation’s patient-centered research network called Citizen Pscientist. This online, interactive community, all
- Miramar Labs to Launch miraSmooth Treatment with FDA Clearance of miraDry For Permanent Reduction of Underarm Hairhttps://practicaldermatology.com/news/miramar-labs-to-launch-mirasmooth-treatment-with-fda-clearance-of-miradry-for-permanent-reduction-of-underarm-hair/2458906/Miramar Labs’ miraDry® System received FDA clearance for the treatment of unwanted underarm hair, and permanent reduction of underarm hair of all colors. Miramar Lab's proprietary miraWave® technology—use of precisely controlled microwave energy—is the founda
- Galderma Receives FDA Approval for Epiduo Forte for Acnehttps://practicaldermatology.com/news/galderma-receives-fda-approval-for-epiduo-forte-for-acne/2458909/The FDA approved Galderma’s antibiotic-free Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical treatment of acne vulgaris. Epiduo Forte Gel is the first combination of these strengths of the retinoid, adapalene, and benzoyl peroxide, developed for
- Heliocare Earns NSF Good Manufacturing Practice Registration For IFC Manufacturing Facilityhttps://practicaldermatology.com/news/heliocare-earns-nsf-good-manufacturing-practice-registration-for-ifc-manufacturing-facility/2458911/Ferndale Healthcare, Inc.’s IFC manufacturing facility for its Heliocare® brand is now a Good Manufacturing Practices (GMP) facility registered by NSF International, an independent organization recognized as the world leader in standards development, product certification, ed
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aestheti
- TV Star, Mother of Four Larsa Pippen Shares Her UltraShape Storyhttps://practicaldermatology.com/news/ultrashape/2458944/UltraShape’s newest devotee, Larsa Pippen, Real Housewives of Miami Alumni, wife of six-time world champion NBA star Scottie Pippen, and fitness enthusiast, recently talked about her UltraShape experience, saying “UltraShape gives me more confidence. I eat well and exercise regularly,
- AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/abbvie-receives-fda-orphan-drug-designation-for-humira-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa/2458945/AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie's su
- R. Scott Peterson Is New Head of Medical Affairs at SkinCeuticalshttps://practicaldermatology.com/news/r-scott-peterson-is-new-head-of-medical-affairs-at-skinceuticals/2458946/R. Scott Peterson, PhD has been named Head of Medical Affairs at SkinCeuticals. In his new role at SkinCeuticals, Dr. Peterson will lead the medical affairs team and expand regional scientific services to support the realization of the company's miss